OPTIC Trial (2019): Omadacycline for Community-Acquired Bacterial Pneumonia
OPTIC Trial Summary: Stets et al. randomized 774 patients with community-acquired bacterial pneumonia (PSI risk class II, III, or IV) diagnosed clinically and with imaging to either omadacycline IV or moxifloxacin IV. The objective was to assess the role of omadacycline, a new tetracycline drug in the treatment of community-acquired bacterial pneumonia. The results showed similar early clinical response in both groups. The authors of OPTIC trial concluded that Omadacycline was noninferior to moxifloxacin for the treatment of community-acquired bacterial pneumonia in adults.